{
    "root": "73eed8f1-3912-40e6-8084-d8498616ee5d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Quetiapine Fumarate",
    "value": "20250210",
    "ingredients": [
        {
            "name": "QUETIAPINE FUMARATE",
            "code": "2S3PL1B6UJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        }
    ],
    "indications": "quetiapine atypical antipsychotic indicated treatment : \u2022 schizophrenia ( 1.1 ) \u2022 bipolar disorder manic episodes ( 1.2 ) \u2022 bipolar disorder , depressive episodes ( 1.2 )",
    "contraindications": "\u2022 quetiapine taken without food . ( 2 . 1 ) indication initial dose recommended dose maximum dose schizophrenia-adults ( 2.2 ) 25 mg twice daily 150 750 mg/day 750 mg/day schizophrenia-adolescents ( 13 17 years ) ( 2.2 ) 25 mg twice daily 400 800 mg/day 800 mg/day bipolar mania-adults monotherapy adjunct lithium divalproex ( 2.2 ) 50 mg twice daily 400 800 mg/day 800 mg/day bipolar mania-children adolescents ( 10 17 years ) , monotherapy ( 2.2 ) 25 mg twice daily 400 600 mg/day 600 mg/day bipolar depression-adults ( 2.2 ) 50 mg daily bedtime 300 mg/day 300 mg/day \u2022 geriatric : consider lower starting dose ( 50 mg/day ) , slower titration careful monitoring initial dosing period elderly . ( 2.3 , 8.5 ) \u2022 hepatic impairment : lower starting dose ( 25 mg/day ) slower titration may needed . ( 2.4 , 8.7 , 12.3 )",
    "warningsAndPrecautions": "quetiapine tablets usp 25 mg tablets supplied round , white off-white , standard biconvex tablet debossed product identification \u201c 54 \u201d \u201c 137 \u201d one side plain side . ndc 0054-0220-25 : bottle 100 tablets ndc 0054-0220-31 : bottle 1,000 tablets ndc 0054-0220-20 : 2 x 5 x 10 unit-dose tablets 50 mg tablets supplied white off-white , oval , standard biconvex tablet debossed product identification \u201c 54 \u201d one side \u201c 377 \u201d side . ndc 0054-0229-25 : bottle 100 tablets ndc 0054-0229-31 : bottle 1,000 tablets ndc 0054-0229-20 : 2 x 5 x 10 unit-dose tablets 100 mg tablets supplied round , white off-white , standard biconvex tablet debossed product identification \u201c 54 \u201d \u201c 373 \u201d one side plain side . ndc 0054-0221-25 : bottle 100 tablets ndc 0054-0221-20 : 2 x 5 x 10 unit-dose tablets 200 mg tablets supplied round , white off-white , standard biconvex tablet debossed product identification \u201c 54 \u201d \u201c 527 \u201d one side plain side . ndc 0054-0222-25 : bottle 100 tablets 300 mg tablets supplied white off-white , oval , standard biconvex tablet debossed product identification \u201c 54 531 \u201d one side plain side . ndc 0054-0223-21 : bottle 60 tablets ndc 0054-0223-20 : 2 x 5 x 10 unit-dose tablets 400 mg tablets supplied white off-white , oval , standard biconvex tablet debossed product identification \u201c 54 735 \u201d one side plain side . ndc 0054-0230-25 : bottle 100 tablets store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ]",
    "adverseReactions": "hypersensitivity quetiapine excipients quetiapine tablet formulation . anaphylactic reported patients treated quetiapine .",
    "indications_original": "Quetiapine is an atypical antipsychotic indicated for the treatment of: \u2022 Schizophrenia ( 1.1 ) \u2022 Bipolar I disorder manic episodes ( 1.2 ) \u2022 Bipolar disorder, depressive episodes ( 1.2 )",
    "contraindications_original": "\u2022 Quetiapine can be taken with or without food. ( 2 .1) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia-Adults ( 2.2 ) 25 mg twice daily 150 to 750 mg/day 750 mg/day Schizophrenia-Adolescents (13 to 17 years) ( 2.2 ) 25 mg twice daily 400 to 800 mg/day 800 mg/day Bipolar Mania-Adults Monotherapy or as an adjunct to lithium or divalproex ( 2.2 ) 50 mg twice daily 400 to 800 mg/day 800 mg/day Bipolar Mania-Children and Adolescents (10 to 17 years), Monotherapy ( 2.2 ) 25 mg twice daily 400 to 600 mg/day 600 mg/day Bipolar Depression-Adults ( 2.2 ) 50 mg once daily at bedtime 300 mg/day 300 mg/day \u2022 Geriatric Use : Consider a lower starting dose (50 mg/day), slower titration and careful monitoring during the initial dosing period in the elderly. ( 2.3 , 8.5 ) \u2022 Hepatic Impairment : Lower starting dose (25 mg/day) and slower titration may be needed. ( 2.4 , 8.7 , 12.3 )",
    "warningsAndPrecautions_original": "Quetiapine Tablets USP \n                  \n                  \n                     25 mg tablets are supplied as a round, white to off-white, standard biconvex tablet debossed with product identification \u201c54\u201d over \u201c137\u201d on one side and plain on the other side.\n                  \n                  NDC 0054-0220-25: Bottle of 100 Tablets\n                  NDC 0054-0220-31: Bottle of 1,000 Tablets\n                  NDC 0054-0220-20: 2 x 5 x 10 Unit-Dose Tablets\n                  \n                     50 mg tablets are supplied as a white to off-white, oval, standard biconvex tablet debossed with product identification \u201c54\u201d on one side and \u201c377\u201d on the other side.\n                  \n                  NDC 0054-0229-25: Bottle of 100 Tablets\n                  NDC 0054-0229-31: Bottle of 1,000 Tablets\n                  NDC 0054-0229-20: 2 x 5 x 10 Unit-Dose Tablets\n                  \n                     100 mg tablets are supplied as a round, white to off-white, standard biconvex tablet debossed with product identification \u201c54\u201d over \u201c373\u201d on one side and plain on the other side.\n                  \n                  NDC 0054-0221-25: Bottle of 100 Tablets\n                  NDC 0054-0221-20: 2 x 5 x 10 Unit-Dose Tablets\n                  \n                     200 mg tablets are supplied as a round, white to off-white, standard biconvex tablet debossed with product identification \u201c54\u201d over \u201c527\u201d on one side and plain on the other side.\n                  \n                  NDC 0054-0222-25: Bottle of 100 Tablets\n                  \n                     300 mg tablets are supplied as a white to off-white, oval, standard biconvex tablet debossed with product identification \u201c54 531\u201d on one side and plain on the other side.\n                  \n                  NDC 0054-0223-21: Bottle of 60 Tablets\n                  NDC 0054-0223-20: 2 x 5 x 10 Unit-Dose Tablets\n                  \n                     400 mg tablets are supplied as a white to off-white, oval, standard biconvex tablet debossed with product identification \u201c54 735\u201d on one side and plain on the other side.\n                  \n                  NDC 0054-0230-25: Bottle of 100 Tablets\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]",
    "adverseReactions_original": "Hypersensitivity to quetiapine or to any excipients in the quetiapine tablet formulation. Anaphylactic reactions have been reported in patients treated with quetiapine."
}